Table 3.
Nuclear and cytoplasmic distribution of RAD51 in prostate cancers with respect to Gleason score
| Cancer grade |
BRCA1/2 cases (combined) |
Controls | ||
|---|---|---|---|---|
| Nuclear | Cytoplasmic | Nuclear | Cytoplasmic | |
| Gleason ≤ 7 | 0/6 (0) | 3/6 (50%) | 8/69 (12%) | 15/69 (22%) |
| Gleason > 7 | 3/11 (27%) | 6/11 (55%) | 7/50 (14%) | 21/50 (42%) |
| p-value | 0.515 | 1.0 | 0.782 | 0.026 |